The sky is the limit - Francois Martelet (Oasmia)
Unlocking Oasmia´s full potential with a board of directors that under promise and over deliver.
Unlocking Oasmia´s full potential with a board of directors that under promise and over deliver.
.
Oasmia utvecklar nästa generations läkemedel, främst inom onkologi. Bolaget är väldigt nära genombrott på marknaden och stora saker har skett i bolaget på kort tid. Nedanstående analys är en lightweig...
The overview contains a lot of information - but leaves the average investor with an impossible mission, to draw any fundamental conclusions - our comment aims to give some valuable input
Oasmia Pharmaceuticals (OASM), is probably the Biotech stock of the year in 2016. Market approval in Russia for Paclical (paclitaxel), enables further market approvals for other cytostatics, bound to...